By Rishika Sadam HYDERABAD (Reuters) -Demand for weight-loss drugs is rising at a fast clip in India, where rivals Eli Lilly ...

NEW DELHI – India is witnessing a sharp rise in the demand for obesity and diabetes medications, with urban populations ...

Demand for weight-loss drugs is rising at a fast clip in India where rivals Eli Lilly and Novo Nordisk are competing for ...

Pharmaceutical giant Cipla plans to enter India's weight management sector, while also bolstering its central nervous system ...

Popular weight-loss drug Wegovy maker Novo Nordisk expects high demand and acceptance for its anti-obesity drug, when launched in India, a top executive said.

New Delhi: Drug major Cipla is preparing to foray into the weight management segment in India, its MD and global CEO Umang ...

The health sector is witnessing notable developments, including the rising demand for obesity drugs in India as Eli Lilly and ...

Incidence of obesity and diabetes is rising in India, the world's most populous country, which also ranks among the worst ...

(Reuters) -Eli Lilly said the response for its blockbuster drug Mounjaro has been "positive" in India, adding that it is focusing on meeting demand for the drug in the world's most populous ...

Eli Lilly & Co. increased sales of weight-loss and diabetes drug Mounjaro 60% in India in May from April in its second full month of being on offer in the South Asian country, which has the ...

STORY: :: Eli LillyDemand for weight-loss drugs in India has shot up.And rivals Novo Nordisk and Eli Lilly are battling for market share.That’s according to research firm Pharmarack.It said ...